We welcome requests for further information or interviews.
Robert Robinson Avenue
The Oxford Science Park
Circassia is a specialty biopharmaceutical business with established commercial infrastructure, marketed products, a pipeline of near-term therapies and portfolio of particle-engineered treatments targeting major market opportunities. Circassia sells its novel, market-leading NIOX® asthma management products directly to specialists in the United States and Germany. Its products are also promoted in a number of other countries by the Company’s network of partners.
Circassia’s broad-based development pipeline includes a range of respiratory medicines. The Company’s lead asthma treatment, Fliveo®, targets substitution of GSK’s Flixotide® pMDI and is approved in the UK and Sweden. Circassia is also developing a direct substitute for Seretide® pMDI, Seriveo®. In addition, the Company’s pipeline includes a number of inhaled medicines for chronic obstructive pulmonary disease, including single and combination dose products.